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ABSTRACT 
 
 
By using an in vitro model of antibody-mediated demyelination, we investigated the 
relationship between tumor necrosis factor-  (TNF- ) and heat shock protein (HSP) 
induction with respect to oligodendrocyte survival. Differentiated aggregate cultures 
of rat telencephalon were subjected to demyelination by exposure to antibodies 
against myelin oligodendrocyte glycoprotein (MOG) and complement. Cultures were 
analyzed 48 hr after exposure. Myelin basic protein (MBP) expression was greatly 
decreased, but no evidence was found for either necrosis or apoptosis. TNF-  was 
significantly up-regulated. It was localized predominantly in neurons and to a lesser 
extent in astrocytes and oligodendrocytes, and it was not detectable in microglial 
cells. Among the different HSPs examined, HSP32 and B-crystallin were up-
regulated; they may confer protection from oxidative stress and from apoptotic death, 
respectively. These results suggest that TNF- , often regarded as a promoter of 
oligodendroglial death, could alternatively mediate a protective pathway through B-
crystallin up-regulation. 
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INTRODUCTION 
 
Multiple sclerosis (MS) and other demyelinating diseases of the central nervous 
system show different patterns of myelin destruction and oligodendrocyte survival, 
suggesting that several pathogenic mechanisms are involved in distinct subtypes of 
the disease (Lucchinetti et al., 1996). One potential demyelinating mechanism seems 
to be linked to the presence of autoantibodies. A pathogenic role for antibodies is 
suggested by observations showing that intact B-cell function is required for full 
expression of experimental allergic encephalomyelitis (EAE), an animal model for 
MS (Gausas et al., 1992), and that antibodies directed against specific CNS antigens, 
such as myelin oligodendrocyte glycoprotein (MOG), have demyelinating activity in 
vivo (Linington and Lassman, 1987) and in vitro (Honegger and Matthieu, 1990; 
Kerlero de Rosbo et al., 1990). Among the different myelin antigens, MOG is of 
particular interest, in that it induces both T-cell activation with a specific pattern of 
inflammation and antibody-induced demyelination (Adelmann et al., 1995). MOG is a 
minor myelin protein (less than 0.05% of total myelin proteins) with an 
immunoglobulin-like extracellular domain and is expressed on the outermost layer of 
the myelin sheath, accessible to antibody attack (Brunner et al., 1989; Amiguet et al., 
1992). Autoantibodies against MOG have been identified within acute MS lesions, 
bound to disintegrating myelin membranes (Genain et al., 1999). 
 
The fate of oligodendrocytes during inflammatory demyelinating processes, such as 
those occurring in MS, is still unsettled (Raine, 1997). In some MS lesions, 
precipitation of immunoglobulins and activated terminal complement components 
seem to be associated with oligodendrocyte survival and remyelination (Storch et al., 
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1998). Several studies in vitro have shown that oligodendrocytes may undergo cell 
death by either necrosis or apoptosis (Selmaj et al., 1991). However, there is still 
controversy concerning oligodendrocyte apoptosis in MS: whereas in chronic 
progressive MS lesions no direct evidence of oligodendrocyte apoptosis was found 
(Bonetti and Raine, 1997), extensive apoptosis was observed in newly forming lesions 
of patients with relapsing and remitting MS (Barnett and Prineas, 2004). This 
suggests that different pathogenic mechanisms are involved in lesion formation 
(Kornek and Lassmann, 2003). 
 
Tumor necrosis factor-  (TNF- ) has been shown to play a prominent role in CNS 
pathologies, including MS. In addition to its proapoptotic action mediated by the TNF 
receptor 1 (TNFR1), it is regarded as a multifunctional proinflammatory cytokine that 
induces a wide range of biological responses, including the activation of 
macrophages/microglia and the direct cytolysis of oligodendrocytes (for review see 
Selmaj and Raine, 1988; Merrill and Scolding, 1999). However, the exact pathogenic 
role of TNF-  in demyelinating processes remains controversial. Recently, EAE 
induced in TNF-  knockout mice has produced contradictory results indicating that 
TNF-  can exert both exacerbating and attenuating effects (Liu et al., 1998; Arnett et 
al., 2001; Matejuk et al., 2002). Moreover, clinical trials aimed at the neutralization of 
TNF-  in MS patients have shown little benefit or even aggravation of the clinical 
symptoms in some patients (van Oosten et al., 1996; The Lenercept Group, 1999). It 
therefore appears that, under certain circumstances, TNF-  can induce specific 
protective mechanisms in oligodendrocytes, analogous to those observed in neurons 
(Bruce et al., 1996). The heat shock response would be one example of these 
putatively protective reactions. 
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Heat shock proteins (HSPs) are produced in response to a wide variety of stressful 
insults and act as molecular chaperones that prevent inappropriate protein-protein 
interactions and aggregation of damaged or misfolded proteins (Hightower, 1991; 
Calabrese et al., 2002). Among HSPs, HSP70 and HSP90 are antiapoptotic by their 
direct inhibition of caspase activation (Beere et al., 2000; Pandey et al., 2000; Saleh et 
al., 2000). Interestingly, in astrocytes in vitro, TNF-  specifically regulates the 
expression of B-crystallin, a member of the HSP family related to HSP27 
(Bajramovic et al., 2000). B-crystallin is constitutively expressed in many tissues, 
such as the lens, the heart, and the skeletal muscle (Clark and Muchowski, 2000). Its 
expression is strongly induced in different types of CNS injury, particularly in MS 
lesions (Bajramovic et al., 1997), where it is also recognized as a dominant T-cell 
antigen in myelin derived from MS patients (Van Noort et al., 1995). Because of its 
chaperone activity, B-crystallin could protect oligodendrocytes during a 
demyelinating episode. 
 
In the present study, the fate of oligodendrocytes was investigated in an established in 
vitro model of antibody-mediated demyelination, by using myelinated aggregating 
brain cell cultures and anti-MOG antibodies plus complement to induce 
demyelination (Honegger and Matthieu, 1990; Kerlero de Rosbo et al., 1990; Pouly et 
al., 2001; Besson Duvanel et al., 2001, 2003). By combining biochemical assays with 
immunocytochemistry and in situ hybridization, cultures were examined for cell 
death, changes in myelination, and expression and localization of TNF-  and HSPs, 
with special emphasis on HSP32 and B-crystallin. 
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MATERIAL AND METHODS 
 
Aggregating brain cell cultures 
Fetal (16 days of gestation) rat telencephalons (OFA; Charles River Laboratories) 
were mechanically dissociated by using nylon sieves with 115- and 200- m pores to 
prepare rotation-mediated aggregating brain cell cultures, as described previously 
(Honegger and Monnet-Tschudi, 2001). The aggregates were maintained in a serum-
free medium (Honegger and Monnet-Tschudi, 2001) under constant rotation at 37°C 
and in an atmosphere of 10% CO2 and 90% humidified air. Every 2 days, 5 ml of 
medium were exchanged per flask out of a total volume of 8 ml. 
 
Antibody mediated demyelination 
At culture day 27, the contents of each culture flask were split into four equal parts, 
and the final volume of each flask was made up to 8 ml by addition of fresh medium. 
Two sets of control cultures were established. The first set was kept untreated, the 
second challenged with complement alone. As a source of complement, we used 
guinea pig serum at a concentration of 25 l/ml of culture medium. Demyelination 
was induced by adding to the cultures a mouse monoclonal antibody against rat MOG 
(62.5 g/ml of culture medium) and complement for 48 hr. This antibody was derived 
from clone 8-18C5 (Linington et al., 1984); the immunoglobulin G (IgG) fraction was 
purified by affinity chromatography by using the Bio-Rad Econo-Pac protein A kit 
(Bio-Rad, Richmond, CA). For biochemical analyses, brain cell aggregates were 
washed twice with 5 ml ice-cold phosphate-buffered saline (PBS) and homogenized 
in 0.5 ml potassium phosphate buffer (2 mM, pH 6.8) containing 1 mM EDTA, with 
glass-glass homogenizers (Bellco, Vineland, NJ). The different homogenates were 
briefly sonicated and stored at -80°C as aliquots for the different assays. For 
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morphological analysis, aggregates were washed with PBS, embedded in tissue 
freezing medium (Jung, Nussloch, Germany), frozen in isopentane cooled with liquid 
nitrogen, and stored at -80°C, as described previously (Honegger and Monnet-
Tschudi, 2001). 
 
 
Biochemical assays 
The protein concentration was measured by the Folin phenol method (Lowry et al., 
1951) with bovine serum albumin as a standard. Radioimmunoassay was used to 
quantify the MBP content (Bürgisser, 1983). The 2 ,3 -cyclic nucleotide 3 -
phosphohydrolase (CNP) activity was measured by using a spectrophotometric 
technique (Kurihara and Tsukada, 1967). The activities of both choline 
acetyltransferase (ChAT), a marker for cholinergic neurons, and glutamic acid 
decarboxylase (GAD), a marker for -aminobutyric acid (GABA)-ergic neurons, 
were determined as described by Wilson et al. (1972). Glutamine synthetase (GS) 
activity, an astrocytic marker, was measured by a modified radioenzymatic method of 
Pishak and Phillips (Patel et al., 1982) with L-[1-14C]glutamic acid as precursor and 
phosphoenolpyruvate/pyruvate kinase as the ATP-generating system. 
 
Apoptosis/necrosis 
The presence of necrotic cells was assessed by measuring the release of lactate 
dehydrogenase (LDH) into the culture medium by a conventional photometric 
technique (Pouly et al., 1997). Apoptosis was determined by two different techniques, 
namely, nucleosomic DNA laddering and terminal deoxynucleotidyl transferase 
tailing reaction (TUNEL). DNA fragmentation analysis was performed essentially as 
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described by Eizenberg et al. (1995). The aggregates were first washed twice in a 
solution of 140 mM NaCl and 20 mM EDTA, then incubated at 37°C in 400 l lysis 
buffer (200 mM Tris-HCl, pH 8.3, 100 mM EDTA, 50 g/ml proteinase K, and 1% 
sodium dodecyl sulfate). DNA was extracted twice with the conventional 
phenol/chloroform method. The aqueous phase containing the DNA was dialyzed 
overnight at 4°C against a solution of 10 mM Tris-HCl, pH 7.5, and 1 mM EDTA. 
This procedure was followed by a 3-hr incubation at 37°C with RNase A (50 g/ml). 
Proteinase K (120 g/ml) was added, and incubation was continued for another 3 hr at 
37°C. DNA was again extracted twice with the conventional phenol/chloroform 
method and then precipitated in ethanol. Pellets were resuspended in 50 l H2O. DNA 
concentrations were measured by spectrophotometry at 260 nm. Five micrograms of 
each DNA sample were subjected to electrophoresis in a 1% agarose gel, and DNA 
fragments were visualized by staining with ethidium bromide. 
 
TUNEL labeling was performed on cryostat sections fixed in a solution of PBS 
containing 4% paraformaldehyde, pH 7.4, for 20 min at room temperature. The 
sections were washed twice with PBS, incubated with a permeabilization solution 
(0.1% Triton X-100, 0.1% sodium citrate) for 2 min on ice, and rinsed twice in PBS. 
In accordance with the manufacturer's instructions (Roche Diagnostics, Mannheim, 
Germany), 50 l TUNEL reaction mixture containing fluorescein-dUTP was added to 
the samples and incubated for 1 hr at 37°C in the dark. For negative controls, the 
terminal transferase step was omitted. Sections were then washed twice with PBS, 
mounted, and analyzed with a fluorescent microscope (Leitz). 
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In situ hybridization 
Digoxigenin-labeled MBP riboprobes were transcribed in vitro from linearized, gel-
purified plasmids by using T7 RNA polymerase as described previously (Tosic et al., 
2002). Cryostat sections were hybridized for 40 hr at 58°C with digoxigenin-labeled 
probes (400 ng/ml) in 5× SSC (NaCl 0.75 M, Na-citrate 0.075 M) containing 50% 
formamide and 40 g/ml salmon sperm DNA (Braissant, 2004). The sections were 
washed three times in decreasing concentrations of SSC and incubated with alkaline 
phosphatase-coupled antidigoxigenin antibody (5,000-fold dilution). The mRNAs 
were visualized by alkaline phosphatase staining. Sections were then dehydrated, 
mounted, and photographed with a light microscope (Leitz). 
 
Gel electrophoresis and immunoblotting 
A solution of antiprotease (Complete Mini; Boehringer/Roche, Indianapolis, IN) was 
added to the homogenized brain cell aggregates. Samples (80 g) were precipitated in 
a fivefold volume of ice-cold acetone at -80°C during 2 hr. After a 30-min 
centrifugation (12,000 rpm at 4°C), the homogenates were solubilized in Laemmli 
buffer (1:1) and loaded on standard (12% w/v acrylamide/0.2% w/v bisacrylamide) 
polyacrylamide gels. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) was then carried out. After separation, gels were blotted onto PVDF 
membranes and blocked for 2 hr at 37°C with 5% nonfat milk in Tris-buffered saline 
(TBS) containing 0.05% (v/v) Tween-20. The immobilized proteins were detected 
after an overnight incubation at 4°C with appropriate antibodies: anti-MOG (1,000-
fold dilution), anti-TNF-  (500-fold dilution), anti- B crystallin (1,000-fold dilution), 
antiheme oxygenase 1 (500-fold dilution; Sigma, St. Louis, MO), anti-HSP27 (500-
fold dilution), anti-HSP70 (500-fold dilution), anti-HSP90 (1,000-fold dilution), and 
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antiactin (500-fold dilution; Sigma) as an internal control. Antibodies against B-
crystallin, TNF- , HSP27, HSP70, and HSP90 were purchased from Calbiochem 
(Darmstadt, Germany). The blots were then washed three times for 5 min each in 
TBS-Tween. The appropriate species-specific horseradish peroxidase-conjugated 
secondary antibody (10,000-fold dilution) was applied for 1 hr at room temperature. 
After three 5-min washes in TBS-Tween, the signal was detected by using an 
enhanced chemiluminescence system (Amersham Pharmacia Biotech, Piscataway, 
NJ). The blots were exposed on BioMax MR-1 films (Kodak, Rochester, NY); then, 
the films were scanned on ImageScanner (Amersham Pharmacia Biotech), and 
semiquantitation was performed with the software analysis system TotalLab 
(Amersham Pharmacia Biotech). 
 
Immunohistochemistry 
Double labeling of cryostat sections was performed to identify the cell type(s) 
expressing TNF-  and B-crystallin. 
 
Double colorimetric immunohistochemistry 
Cryostat sections (8 m) were fixed 1 hr with 4% paraformaldehyde (PFA) in PBS. 
Endogenous peroxidase activity was bleached with 1.5% H2O2 for 15 min. After 
blockade of nonspecific binding with 1% bovine serum albumin (BSA) in PBS, 
sections were exposed 1 hr to rabbit polyclonal antibodies against TNF-  (1:30; 
Biosource International) or B-crystallin (1:400; Calbiochem) diluted in PBS 
containing 1% BSA. After being washed, sections were processed using the 
Histostain-Plus kit according to the manufacturer's protocol (Zymed Laboratories, 
South San Francisco, CA): Sections were incubated with a biotinylated anti-rabbit 
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IgG secondary antibody, followed by a streptavidin-peroxidase conjugate. Peroxidase 
staining was performed for 30 min with aminoethyl carbazole and H2O2 (red signal) 
and was stopped in distilled water. To identify oligodendrocytes expressing TNF-  or 
B-crystallin, some of the cryosections were subjected to a second 
immunohistochemical procedure for the labeling of the oligodendrocytic marker 
galactocerebroside (Gal-C). After blockade of nonspecific binding with 1% BSA in 
PBS, sections were exposed 1 hr to a mouse monoclonal antibody against Gal-C 
(1:20; Chemicon, Temecula, CA) diluted in 1% BSA in PBS. After being washed, 
sections were incubated for 1 hr with a goat anti-mouse IgG antibody coupled to 
alkaline phosphatase (1:500; Bio-Rad). Sections were finally stained (15 min) with 
nitroblue tetrazolium (NBT) and 5-bromo-4-chloro-3-indolyl-phosphate (BCIP; blue 
signal). Levamisole (1%) was used in the staining buffer to block endogenous alkaline 
phosphatase activity. The labeling was stopped in 10 mM Tris containing 1 mM 
EDTA. Sections were mounted under glycerol and observed and photographed on an 
Olympus BX50 microscope equipped with a DP-10 digital camera (Olympus 
Opticals). 
 
Double confocal immunofluorescence 
Cryostat sections (10 m) were fixed for 10 min in acetone at room temperature and 
dried overnight at 4°C (Honegger and Monnet-Tschudi, 2001). For blockade of 
nonspecific binding, sections were first incubated with a mixture of goat serum and 
donkey serum (1:20 in PBS with 0.1% Triton X-100; Jackson Immunoresearch, West 
Grove, PA) and exposed overnight at 4°C with polyclonal antibodies against either 
B-crystallin (1:200; Calbiochem) or TNF-  (1:15; Biosource International) and with 
cell specific antibodies: Monoclonal antibodies against microtubule-associated protein 
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2 (MAP-2; 1:125; Biomarker) or synaptophysin (1:25; Chemicon), two markers for 
neurons; glial fibrillary acidic protein (GFAP; 1:200; Sigma), a marker for astrocytes; 
or MBP (1:200; Chemicon), a marker for oligodendrocytes. Isolectin B4 of Griffonia 
simplicifolia bound to fluorescein isothiocyanate (IB4 bound to FITC; 1:20; Sigma) 
was used as a marker for microglia. With polyclonal antibodies, the staining was 
developed with the avidin-biotin system [goat anti-rabbit biotinylated IgG; 1:100; 
FITC-labeled avidin (DCS); 1:50, Vector, Burlingame, CA]. With monoclonal 
antibodies, staining was obtained with donkey anti-mouse IgG bound to Cy3 (1:250; 
Jackson Immunoresearch). Monoclonal antibodies applied together with IB4 bound to 
FITC were stained with donkey anti-mouse IgG bound to Cy3. Sections were 
mounted in Fluosave Reagent (Calbiochem) and analyzed with a Leica confocal 
microscope. For one final image, 10 confocal images taken at steps of 1 m were 
superposed. To verify a nuclear localization of B-crystallin, double-labeled sections 
were incubated for 30 min at 37°C in a solution of 4 ,6-diamidino-2-phenylindole 
(DAPI; 1 mg/ml; Sigma). Sections were observed with a Leica fluorescence 
microscope with appropriate filters. 
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RESULTS 
 
Anti-MOG antibodies and complement caused demyelination without a significant 
increase of cell death 
In myelinated aggregating rat brain cell cultures, the addition of anti-MOG antibodies 
and complement significantly decreased the levels of MOG within 48 hr (Fig. 1, lane 
3). Similarly, CNP activity taken as a marker of the uncompacted oligodendroglial 
membranes and MBP content as a marker of mature myelin were significantly 
decreased (Table I). MBP was also significantly decreased at the transcriptional level 
as shown by in situ hybridization (Fig. 2). Throughout, comparisons were made with 
untreated control cultures as well as with cultures treated with complement alone, the 
latter for the evaluation of possible toxic effects of complement on oligodendrocytes 
(Scolding et al., 1990). As shown in Table I, complement alone decreased both MBP 
content and CNP activity, although not to a statistically significant extent. The reason 
for these effects remain obscure, whether they are due to the inherent toxicity of 
complement or of other components in the guinea pig serum, which served as a source 
of complement. In contrast to the oligodendroglial markers, the presence of 
complement alone increased the levels of ChAT, GAD, and GS specific activities 
(Table I), as was found previously (Kerlero de Rosbo et al., 1990; Besson Duvanel et 
al., 2001). These stimulatory effects may be attributed to the presence of trophic 
factors in the guinea pig serum, as discussed previously (Kerlero de Rosbo et al., 
1990). 
 
Measurements of the LDH activity in treated cultures and in untreated controls 
showed no significant variation (Table I), indicating that neither the addition of 
complement alone nor the combination of complement and anti-MOG antibodies 
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caused necrotic cell death. Furthermore, the absence of nucleosomic DNA laddering 
(Fig. 3) indicated that the apoptotic cell death was not increased either. In accordance 
with these findings, no evidence for apoptotic death was found in the TUNEL labeling 
assay or in the Western blot analysis of p53 (results not shown). 
 
Upregulation of TNF-α during demyelination and cellular localization of TNF−α 
Aggregate cultures subjected to demyelination were examined for TNF-  expression 
by Western blot analysis (Fig. 4) and immunohistochemistry (Fig. 5). The results 
show that, under demyelinating conditions, TNF-  was up-regulated (Fig. 4, lane 3; 
Fig. 5c) compared with the basal levels found in untreated controls (Fig. 4, lane 1; 
Fig. 5a) and those found in cultures treated with complement alone (Fig. 4, lane 2; 
Fig. 5b). The latter indicated that complement alone did not affect the levels of TNF-
. The cellular expression of TNF-  was further examined by double immunostaining 
(Fig. 5d-l). TNF-  was always located in oligodendrocytes (Fig. 5d-f, colabeled for 
Gal-C): in untreated controls (Fig. 5d), after treatment with complement alone (Fig. 
5e), and after treatment with complement and anti-MOG antibodies (Fig. 5f). The 
presence of TNF-  in oligodendrocytes was also demonstrated by colabeling for MBP 
(not shown). However, TNF-  was expressed mainly in astrocytes (Fig. 5g-i, 
colabeled for GFAP) and in neurons (Fig. 5j-l, colabeled for synaptophysin). TNF-  
was not detectable in microglial cells (not shown). 
 
Upregulation of αB-crystallin and HSP32 during demyelination and cellular 
localization od αB-crystallin 
Analysis by Western blotting of the expression of HSPs showed that, of the five HSPs 
tested (i.e., HSP32, HSP27, HSP70, HSP90, and B-crystallin), only two (HSP32 and 
B-crystallin) were specifically up-regulated by the anti-MOG-induced 
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demyelination (Fig. 6). HSP32 was found at low levels in untreated cultures (Fig. 6, 
lane 1). Its expression was increased after the addition of complement (Fig. 6, lane 2) 
and further increased in demyelinating cultures (Fig. 6, lane 3). B-crystallin was 
weakly expressed in untreated controls (Fig. 6, lane 1) and in complement-treated 
cultures (Fig. 6, lane 2), whereas it was strongly up-regulated under demyelinating 
conditions (Fig. 6, lane 3). In contrast, no change was found for HSP 90 (Fig. 6) and 
HSP 70 (not shown), but HSP27 was slightly, but not significantly, decreased in the 
treated cultures (Fig. 6). 
 
At the histological level, B-crystallin was also found to be up-regulated in 
demyelinating cultures (Fig. 7c) compared with untreated controls (Fig. 7a) and 
cultures treated with complement alone (Fig. 7b). As for TNF-  (Fig. 4, 5) and as 
observed by Western blotting (Fig. 6), no effect of complement alone could be 
observed for B-crystallin at the histological level. B-crystallin was further analyzed 
at the cellular level by double immunostaining (Fig. 7d-l). As for TNF- , B-
crystallin was demonstrated in oligodendrocytes by colabeling for Gal-C (Fig. 7d-f) 
and MBP (not shown) in untreated controls (Fig. 7d), after treatment with 
complement alone (Fig. 7e), and after treatment with complement and anti-MOG (Fig. 
7f). However, most of the B-crystallin expression was localized in astrocytes (Fig. 
7g-l, colabeled for GFAP), where a punctated staining was observed in the nuclei both 
in untreated controls (Fig. 7g-i) and in demyelinating cultures (Fig. 7j-l, observed 
after lowering of the FITC signal threshold). The nuclear localization of B-crystallin 
was further confirmed with DAPI as nuclear dye (not shown). The increased staining 
of GFAP observed in demyelinating cultures (Fig. 7k compared with h) suggests that, 
under these conditions, the astrocytes were in a reactive state. 
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DISCUSSION 
 
For MS and EAE, several demyelinating mechanisms have been proposed, including 
the direct immune attack against specific myelin components (Brosnan and Raine, 
1996), activation of cytokine receptors of oligodendrocytes (Dowling et al., 1996), 
and generation of reactive oxygen and nitrogen intermediates (Merrill and Benveniste, 
1996). Strong evidence for autoimmune antibody-mediated demyelination stems from 
the detection of anti-MOG immunoglobulins associated with myelin damage in MS 
(Genain et al., 1999). MOG is of particular interest, in that it is so far the only myelin 
antigen known that elicits both a T-cell-mediated inflammatory immune response and 
antibody-mediated demyelination (Adelmann et al., 1995). With respect to the MS 
lesions showing oligodendrocyte survival and remyelination, it is noteworthy that 
they are associated with local precipitation of immunoglobulins and activated terminal 
complement components (Storch et al., 1998). These observations suggest that 
antibody-mediated demyelination induces secondary reactions that may attenuate 
further immunological attacks. 
 
The fate of oligodendrocytes during demyelination is still a matter of debate (Raine, 
1997). Although the apoptotic death of oligodendrocytes has been observed under 
various circumstances (Selmaj et al., 1991; Casaccia-Bonnefil, 2000), its occurrence 
in MS lesions has been questioned (Bonetti et al., 1997; Barnett and Prineas, 2004). In 
the present study, there was no sign of apoptosis after antibody-mediated 
demyelination in three-dimensional brain cell cultures, despite the drastic decrease of 
myelin-specific markers. The concomitant reduction in MBP mRNA levels may 
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indicate dedifferentiation of oligodendrocytes, in accordance with previous 
observations after phorbolester-induced demyelination (Pouly et al., 1997). 
 
Among the potential mediators of MS pathogenesis, the proinflammatory cytokine 
TNF-  has often been associated with oligodendrocyte injury and cell death (D'Souza 
et al., 1995). However, its exact role in oligodendrocyte injury and demyelination 
remains unclear. One of the reasons may be the existence of two different TNF-  
receptors, TNFR1 (p55) and TNFR2 (p75; Brockhaus et al., 1990). Both receptors 
have been implicated in apoptotic mechanisms, although TNFR1 appeared as the 
principal mediator of cell death, whereas TNFR2 also promoted cell activation, 
growth, and proliferation (Nagata, 1997). There are diverging reports concerning the 
expression of TNFR1 and/or TNFR2 by oligodendrocytes in vivo and in vitro (for 
review see Hisahara et al., 2003). In any case, evidence for TNFR1-mediated 
apoptosis in vivo is lacking (Bonetti and Raine, 1997). In the present in vitro model of 
MOG antibody-mediated demyelination, TNF-  expression was up-regulated. 
Whether it was also released by the cells could not be determined; the 
inmmunohistochemical approach did not allow to differentiate between intracellular 
and extracellularly bound TNF- . At any rate, despite the up-regulation and possible 
release of TNF- , there was no apparent change in the viability of the 
oligodendrocyte population. In EAE models, a prolonged increase of TNF-  
production has been described for neurons (Villarroya et al., 1997; Shin et al., 1999), 
suggesting a protective role in neurons. TNF-  may protect neurons from axonal 
degeneration by the modulation of synaptic activity (Elenkov et al., 1992), 
adrenocorticotropic hormone (ACTH) secretion (Sharp et al., 1989), and/or nerve 
growth factor synthesis (Gadient et al., 1990). 
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Could antiapoptotic pathways be specifically triggered in oligodendrocytes during 
demyelination? Recent studies have demonstrated that HSP70 and HSP90 impede 
caspase activation (Beere et al., 2000; Pandey et al., 2000; Saleh et al., 2000). 
However, these two HSPs remained unchanged during the anti-MOG-induced 
demyelination, whereas HSP32 and B-crystallin were up-regulated. HSP32, also 
known as heme oxygenase 1, belongs to a family of proteins that catalyze the 
oxidative degradation of heme to biliverdin. Heme increases the formation of reactive 
oxygen intermediates and, hence, exacerbates intracellular oxidative stress (Schipper, 
2000). HSP32 is up-regulated in oligodendrocytes after an oxidative stress (Goldbaum 
and Richter-Landsberg, 2001), but it remains controversial whether an increased 
HSP32 level confers protection or rather aggravates cell damage (Schipper, 2000). At 
any rate, the present finding that HSP32 was strongly up-regulated during antibody-
mediated demyelination indicates the involvement of oxidative stress in the 
pathogenesis of demyelination. B-crystallin is related to HSP27, a member of the 
family of small HSPs. Small HSP members contain a highly conserved domain 
known as the -crystallin core, located in the C-terminal part of the protein (Clark 
and Muchowski, 2000). They form oligomeric complexes with partners of the same 
family that function as molecular chaperones to facilitate protein folding and to 
prevent aggregation of denatured or misfolded proteins. Recently, B-crystallin was 
reported to inhibit a downstream effector of the death receptor pathway and to 
regulate apoptosis in the cell negatively (Kamradt et al., 2001). Thus, B-crystallin 
could be able to prevent TNF- -induced apoptosis. Binding of TNF-  to its receptor 
recruits and activates procaspase-8 via a series of protein-protein interactions (Garrido 
et al., 2001). Active caspase-8 cleaves procaspase-3 to generate a p24 intermediate. 
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B-crystallin inhibits the autoproteolytic formation of p24 necessary for the generation 
of active caspase-3, the final trigger of apoptosis in the cell. During MOG antibody-
mediated demyelination in the aggregates, B-crystallin was strongly up-regulated. 
Although the levels of HSP27, its oligomeric partner for molecular chaperone 
activity, decreased slightly during demyelination, sufficient protein might have been 
available to contribute to an antiapoptotic effect. 
 
The up-regulation of B-crystallin during demyelination may be directly linked to the 
up-regulation of TNF- , in that the latter is the only cytokine reported to up-regulate 
specifically the expression of B-crystallin in cultured astrocytes (Bajramovic et al., 
2000). In aggregate cultures, B-crystallin is up-regulated during demyelination in 
astrocytes and oligodendrocytes. Furthermore, a nuclear location was found for B-
crystallin in astrocytes, similar to that reported by Bajramovic et al. (2000). Taken 
together, the present results suggest that, during antibody-mediated demyelination, 
TNF-  triggered a protective pathway for oligodendrocytes via up-regulation of B-
crystallin. 
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Table I. Effects of Anti-MOG Antibodies and Complement on Myelin, Oligodendrocytes, 
Cholinergic and GABAergic Neurons, Astrocytes, and Extracellular LDH Release  
 Control cultures  
Complement 
(25 l/ml) 
Anti-MOG (62.5 g/ml) 
and complement 
Total protein (mg/flask) 2.6 ± 0.2 2.95 ± 0.2 2.95 ± 0.2 
MBP ( g/mg total protein) 0.64 ± 0.05 0.52 ± 0.04 0.18 ± 0.02* 
CNP ( mol of 2 -NADP · min-
1/mg total protein) 
3.52 ± 0.4 2.39 ± 0.3 1.83 ± 0.23* 
ChAT (pmol · min-1/mg total 
protein) 
355.2 ± 49.2 529.3 ± 56.0 410.8 ± 58.9 
GAD (nmol · min-1/mg total 
protein) 
1,103.6 ± 111.8 1,565.3 ± 77.1 1,499.8 ± 95.2 
GS ( mol · min-1/mg total 
protein) 
1.99 ± 3.1 2.45 ± 1.8 2.35 ± 2.5 
LDH ( mol · min-1/flask) 0.26 ± 0.01 0.29 ± 0.01 0.27 ± 0.01  
   Data are mean ± SEM from five independent experiments. 
  * P < 0.01 (ANOVA and Dunnet's posttest). 
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LEGENDS 
 
Fig. 1 Demyelination-induced down-regulation of MOG in aggregating rat brain cell 
cultures. Western blot analysis of MOG and actin in untreated controls (lane 1), in 
cultures treated with complement alone (lane 2), and in anti-MOG- and complement-
treated aggregates (lane 3). Densitometric quantitation of MOG of blotted 
homogenates. Actin was used as an internal standard to correct for the difference in 
protein amounts. Data are mean ± SEM (n = 5). *P < 0.05. 
 
Fig. 2 Demyelination-induced decrease in the expression of MBP mRNA. The 
transcriptional activity of the MBP gene in aggregates was detected by in situ 
hybridization. No signal was observed with the sense probes that were used as an 
internal control to ensure specific hybridization of the MBP mRNA (not shown). 
Untreated control culture (a,d), complement (b,e), and anti-MOG and complement 
(c,f); d-f are higher magnifications of a-c, respectively. 
 
Fig. 3 Absence of apoptosis in aggregating brain cell cultures after antibody-mediated 
demyelination. Detection of apoptotic cells was done by DNA laddering. DNA was 
extracted from untreated control cultures (lane 1), complement-treated cultures (lane 
2), anti-MOG- and complement-treated aggregates (lane 3), and a negative control of 
nonapoptotic primary cultures of oligodendrocytes (lane 4). A DNA molecular weight 
marker was also loaded. The bands were visualized by using ethidium bromide under 
UV exposure. 
 
Fig. 4  Demyelination-induced up-regulation of TNF-  in aggregating rat brain cell 
cultures. Western blot analysis of TNF-  in untreated controls (lane 1), in cultures 
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treated with complement alone (lane 2), and in anti-MOG- and complement-treated 
aggregates (lane 3). A densitometric quantitation of TNF-  of blotted homogenates 
was made. Actin was used as an internal standard to correct for the difference in 
protein amounts. Data are mean ± SEM (n = 5). *P < 0.05. 
 
Fig. 5 Immunohistochemistry showing the demyelination-induced up-regulation of 
TNF-  and the cellular expression of TNF-  in demyelinating brain cell aggregate 
cultures. TNF-  labeling with peroxidase (a-c), control conditions (a), complement 
alone (b), anti-MOG antibody and complement (c). Cellular localization of TNF-  by 
double colorimetric immunohistochemistry (d-f) and double immunofluorescence and 
confocal microscopy (g-l). Control conditions (d,g-l), complement alone (e), anti-
MOG antibody and complement (f). Localization of TNF-  (red signal) in 
oligodendrocytes colabeled for Gal-C (blue signal; d-f). Localization of TNF-  
(FITC; g) in astrocytes colabeled for GFAP (Cy3; h), and merged (i). Localization of 
TNF-  (FITC; j) in neurons colabeled for synaptophysin (Cy3; k) and merged (l). 
Scale bar in c = 100 m for a-c; bar in f = 25 m for d-f; bar in l = 10 m for g-l. 
 
Fig. 6 Western blot analyses of different HSPs and semiquantitation of B-crystallin, 
HSP32, and actin. B-crystallin and HSP32 were up-regulated after antibody-
mediated demyelination. A: Western blot analysis of different HSPs using antibodies 
to HSP90, HSP32, actin, HSP27, B-crystallin in untreated controls (lane 1), in 
cultures treated with complement alone (lane 2), and in anti-MOG- and complement-
treated aggregates (lane 3). B: Densitometric quantitation of B-crystallin (open bars) 
and HSP32 (solid bars) of blotted homogenates (A). Actin was used as an internal 
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standard to correct for the difference in protein amounts. Data are mean ± SEM (n = 
3). *P < 0.05. 
 
Fig. 7 Immunohistochemistry showing the demyelination-induced up-regulation of 
B-crystallin and the cellular expression of B-crystallin in demyelinating brain cell 
aggregate cultures. B-crystallin labeling with peroxidase (a-c), control conditions 
(a), complement alone (b), anti-MOG antibody and complement (c). Cellular 
localization of B-crystallin by double colorimetric immunohistochemistry (d-f) and 
double immunofluorescence and confocal microscopy (g-l). Control conditions (d,g-
i), complement alone (e), anti-MOG antibody and complement (f,j-l). Localization of 
B-crystallin (red signal) in oligodendrocytes colabeled for Gal-C (blue signal; d-f). 
Localization of B-crystallin (FITC; g,j) in astrocytes colabeled for GFAP (Cy3; h,k) 
and merged (i,l). Scale bar in c = 100 m for a-c; bar in f = 25 m for d-f; bar in l = 
10 m for g-l.  
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